SIGHT SCIENCES INC

SGHT represents Sight Sciences, Inc., a commercial-stage healthcare company focused on developing and commercializing devices for eye care. Its portfolio targets glaucoma and dry eye disease, addressing unmet needs in ophthalmology and optometry. The company operates primarily in the United States, selling to eye care professionals and surgical centers. SGHT is listed on the Nasdaq Global Select Market under the ticker SGHT.

Recent performance for SGHT depends on market trading and company-specific news. For the latest price changes, daily percentage moves, and recent trends, refer to the current SGHT quote and chart displayed on this page. That data reflects the most up-to-date market activity, including intraday and prior close comparisons. Historical performance can provide context, but it does not guarantee future results.

Valuation for SGHT can be assessed using metrics such as price-to-sales, price-to-book, and enterprise value-to-revenue, since the company may not have consistent positive earnings. Compare these ratios with peers in the medical device and eye care sectors. Also review growth trends, cash burn, and path to profitability. For current valuation multiples, use the latest SGHT data displayed on this page rather than relying on outdated figures.

SGHT can be traded in pre-market and after-hours sessions through many brokerages that support extended-hours trading. These sessions typically have lower liquidity, wider spreads, and higher volatility than regular market hours. Availability depends on your broker and the venue. For the latest extended-hours quotes, check the SGHT data on this page.

SGHT, as Sight Sciences, has not historically paid a regular dividend. The company has focused on reinvesting capital into product development, clinical trials, and commercial expansion rather than returning cash to shareholders. Dividend policies can change over time, so check the latest SGHT dividend information on this page for any updates. Any future dividend decision would depend on factors like profitability, cash needs, and board approval.

Key risks for SGHT include regulatory hurdles and reimbursement uncertainties for its eye care devices, competition from larger medical device firms, and reliance on successful clinical adoption. As a smaller-cap company, it may face limited financial resources and potential share dilution. Macro factors such as hospital capital spending and interest rates can also affect results. Review SGHT's SEC filings and latest disclosures for detailed risk factors.